ArticleScientific reports2025
The prognostic value and functional role of CPSF3 in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The identification of reliable biomarkers is critical for improving the diagnosis and treatment of hepatocellular carcinoma (HCC). Cleavage and polyadenylation specific factor 3 (CPSF3) has been implicated in RNA processing and tumor progression, but its role, clinical significance, and functional mechanisms in HCC remain unclear. In this study, we systematically evaluated CPSF3 expression and its potential role in HCC through multi-omics analyses and experimental validation. We observed significant CPSF3 upregulation in HCC tissues in multiple cohorts, and its upregulation was associated with advanced AJCC stage and poor survival. A prognostic nomogram incorporating CPSF3 and AJCC stage showed excellent predictive performance for HCC. CPSF3 demonstrated high diagnostic accuracy in HCC in TCGA and ICGC datasets. Functional experiments revealed that CPSF3 knockdown suppressed HCC cell proliferation, migration, and invasion while promoting apoptosis. Single-cell sequencing analysis revealed predominant CPSF3 expression in malignant cells and proliferating T cells in HCC. CPSF3 expression in HCC correlated with immune cell infiltration and was enriched in cell cycle and MAPK signaling pathways. These findings establish CPSF3 as a promising diagnostic and prognostic biomarker and highlight its potential as a therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.